Pricing Log in Create free account

Actinium Pharmaceuticals, Inc. (ATNM) vs TransCode Therapeutics Inc. (RNAZ)

Actinium Pharmaceuticals, Inc. and TransCode Therapeutics Inc. are both Biotechnology companies. Actinium Pharmaceuticals, Inc. and TransCode Therapeutics Inc. are of similar size ($33.3M and $30.5M). TransCode Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Actinium Pharmaceuticals, Inc. trades at 3.1×. Actinium Pharmaceuticals, Inc. has the higher net margin (32.2% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Actinium Pharmaceuticals, Inc. leads on 7 and TransCode Therapeutics Inc. on 4.

Valuation

Metric ATNM RNAZ Biotechnology median
P/E 3.14 n/m 8.50
P/S 1.01 n/m 9.71
P/B 1.17 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.10 0.64
EV/Sales (0.03) n/m 9.21
Earnings yield 31.86% (3,080.59%) (33.15%)
Free cash flow yield (65.52%) (1,390.70%) (25.50%)

Profitability

Metric ATNM RNAZ Biotechnology median
Gross margin 98.71% 0.00% 65.16%
Operating margin 27.20% 0.00% 0.00%
Net margin 32.18% 0.00% 0.00%
Free cash flow margin (66.16%) 0.00% 0.00%
Return on equity 45.86% 429.61% (56.36%)
Return on assets 21.92% (58.12%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ATNM RNAZ Biotechnology median
Revenue growth (TTM) 2,731.18% — 6.02%
EPS growth (last fiscal year) 14.17% 96.02% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ATNM RNAZ Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.08 1.97 4.72
Net debt to EBITDA 1.35 0.64 0.96

Dividend

Metric ATNM RNAZ Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ATNM RNAZ Biotechnology median
Market cap 33.32m 30.48m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack